Geron Corporation
$1.56
0%
2026-04-21 07:03:01
www.geron.com
NMS: GERN
Explore Geron Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.02 B
Current Price
$1.56
52W High / Low
$2.01 / $1.04
Stock P/E
—
Book Value
$0.35
Dividend Yield
—
ROCE
-11.23%
ROE
-32.99%
Face Value
—
EPS
$-0.13
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
258
Beta
0.67
Debt / Equity
54.01
Current Ratio
4.66
Quick Ratio
3.62
Forward P/E
20.88
Price / Sales
5.82
Enterprise Value
$833.78 M
EV / EBITDA
-16.32
EV / Revenue
4.53
Rating
None
Target Price
$3.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enliven Therapeutics, Inc. | $46.41 | — | $2.88 B | — | -26.04% | -26.95% | $48.53 / $14.79 | $7.73 |
| 2. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 3. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
| 4. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 5. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 6. | Equillium, Inc. | $2.01 | — | $127.09 M | — | -81.63% | -94% | $2.7 / $0.27 | $0.47 |
| 7. | Fulcrum Therapeutics, Inc. | $7.94 | — | $552.12 M | — | -24% | -25.3% | $15.74 / $2.92 | $5.24 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 48.02 M | 47.23 M | 49.04 M | 39.6 M | 47.54 M | — |
| Operating Profit | -8.51 M | -13.89 M | -12.45 M | -16.7 M | -20.05 M | — |
| Net Profit | -28.86 M | -18.43 M | -16.38 M | -19.84 M | -25.35 M | — |
| EPS in Rs | -0.05 | -0.03 | -0.03 | -0.03 | -0.04 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 183.88 M | 76.99 M | 0.24 M | 0.6 M |
| Operating Profit | -51.55 M | -173.73 M | -193.94 M | -138.55 M |
| Net Profit | -83.5 M | -174.57 M | -184.13 M | -141.9 M |
| EPS in Rs | -0.13 | -0.27 | -0.29 | -0.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 570.54 M | 593.78 M | 394.08 M | 190.57 M |
| Total Liabilities | 344.67 M | 313.46 M | 146.13 M | 110.58 M |
| Equity | 225.87 M | 280.32 M | 247.95 M | 80 M |
| Current Assets | 520.27 M | 490.99 M | 341.35 M | 180.25 M |
| Current Liabilities | 111.54 M | 88.3 M | 108.07 M | 76.69 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -111.04 M | -218.62 M | -167.74 M | -127.38 M |
| Investing CF | 107.25 M | -106 M | -180.32 M | 62.07 M |
| Financing CF | 2.27 M | 334.37 M | 362.02 M | 87.26 M |
| Free CF | -111.09 M | -219.3 M | -168.57 M | -127.81 M |
| Capex | -0.05 M | -0.68 M | -0.83 M | -0.43 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 32386.92% | -60.23% | — | — |
| Earnings Growth % | 5.19% | -29.76% | — | — |
| Profit Margin % | -226.73% | -77690.72% | -23808.89% | — |
| Operating Margin % | -225.64% | -81832.91% | -23246.64% | — |
| Gross Margin % | 98.37% | 100% | 100% | — |
| EBITDA Margin % | -201.12% | -73747.68% | -22508.56% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.